CNBCPfizer will combine its off-patent drug business with MylanJul 29, 2019Meg TirrellBy Meg Tirrellmore_vert
FiercePharmaMylan CEO Bresch set to exit after years of controversy—and one last big dealJul 29, 2019Eric SagonowskyBy Eric Sagonowskymore_vert
The New York TimesPfizer to Merge Its Off-Patent Drug Unit With Mylan (Published 2019)Jul 29, 2019Katie Thomas & Michael de la MercedBy Katie Thomas & Michael de la Mercedmore_vert
The Business JournalsRetiring CEO Heather Bresch leaves a legacy of growth at Mylan - BizwomenJul 29, 2019Anne StychBy Anne Stychmore_vert
FiercePharmaPfizer's big split is finally here, thanks to a giant generics merger with MylanJul 29, 2019Angus LiuBy Angus Liumore_vert
Full CoverageFull Coverage